Agreement - August 18, 2021
Alligator Bioscience enters agreement with Orion
Alligator Bioscience has entered into a research collaboration and license agreement with Orion Corporation to discover and develop together new bispecific antibody cancer therapeutics. The research collaboration will focus on the discovery of novel bispecific antibodies directed towards immuno-oncology targets selected by Orion. The agreement covers an option to develop three bispecific antibodies. Under the […]
Pharma Business - April 30, 2019
Orion’s NDA accepted for review and darolutamide granted Priority Review
Orion Corporation and Bayer have announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for review and granted Priority Review for darolutamide for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC) in the U.S. The NDA and Priority Review status were based on data from the Phase III […]
Pharma Business - March 8, 2019
Orion submitts Darolutamide for European marketing authorization
Orion Corporation and Bayer have announced that a marketing authorization application (MAA) has been submitted to the European Medicines Agency (EMA) for darolutamide for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC). Regulatory submission is based on positive data from Phase III study . ARAMIS trial The submission to the EMA is based on […]
Pharma Business - April 23, 2018
Orion to sell its diagnostica division
Orion Corporation has signed an agreement on the sale of all shares in Orion Diagnostica Oy (i.e. the Orion Diagnostica business division) to an investment fund managed by Axcel Management A/S, a Nordic private equity investment company. The fixed purchase price is approximately EUR 163 million. In addition, Orion has a possibility to receive as a […]
Collaboration - September 6, 2016
Orion in collaboration with Menarini Group
Orion Corporation has entered into a collaboration agreement with Menarini Group, for the co-marketing of budesonide-formoterol Easyhaler combination product in Germany, Italy, Spain, and Portugal. In addition, the parties have agreed on an exclusive license and distribution arrangement in France and Turkey. Both companies will market budesonide-formoterol Easyhaler for the treatment of asthma and COPD […]
Pharma Business - May 3, 2016
Fermion invests in new production facility
Fermion, a manufacturer of active pharmaceutical ingredients, and a wholly owned subsidiary of Orion Corporation will build a new production plant to the Hanko manufacturing site in Finland. The construction work will begin in spring 2016 and the new facility is scheduled for completion in 2018. The investment is valued at more than EUR 30 […]
